Loading…
Loading…
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
Acumen Wealth Advisors LLC lessened its holdings in Merck and Co., Inc. (NYSE: MRK) by 25.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,226 shares of the company's stock after selling 9,324 shares during the quarter. Merck and Co., Inc.
Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for what could become the first regimen of its kind for the disease.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacap.
Andra AP fonden trimmed its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 14.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 364,485 shares of the company's stock after selling 63,615 shares during the period. Merck and Co., Inc. makes up about
Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.
For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on July 16, 2026, when the U.S. Food and Drug Administration approved the first oral PCSK9 inhibitor, a class of powerful cholesterol drugs that until now existed only as an injection.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for MRK and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.